Diadem, the developer of a blood test for the early prediction of progression to Alzheimer’s disease, on Monday announced it has joined Dementias Platform UK (DPUK) as a corporate partner.
Diadem's AlzoSure Predict blood test identifies signs of cognitive impairment that will or will not progress to Alzheimer's dementia up to six years before diagnosis.
DPUK is a public-private partnership facilitating ways to understand, diagnose, and treat dementia. It offers access to information on more than 3 million individuals from 50 long-term health cohort studies and, according to Diadem, enables collaboration among academics, regulators, healthcare providers, patients, and the public.
According to Diadem CEO Paul Kinnon, the firm expects to benefit from access to "patient databases and portals and related resources DPUK and its members have assembled, enabling us to further validate and extend the diagnostic utility of our proprietary biomarker technology."